- Home
- ENSC vs SILO Comparison
ENSC vs SILO Comparison
Compare ENSC & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- SILO
- Stock Information
- Founded
- ENSC 2003
- SILO 2010
- Country
- ENSC United States
- SILO United States
- Employees
- ENSC N/A
- SILO N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- ENSC Health Care
- SILO Consumer Discretionary
- Exchange
- ENSC Nasdaq
- SILO Nasdaq
- Market Cap
- ENSC 5.2M
- SILO 4.5M
- IPO Year
- ENSC N/A
- SILO N/A
- Fundamental
- Price
- ENSC $2.15
- SILO $0.70
- Analyst Decision
- ENSC
- SILO
- Analyst Count
- ENSC 0
- SILO 0
- Target Price
- ENSC N/A
- SILO N/A
- AVG Volume (30 Days)
- ENSC 874.4K
- SILO 711.7K
- Earning Date
- ENSC 08-13-2025
- SILO 08-19-2025
- Dividend Yield
- ENSC N/A
- SILO N/A
- EPS Growth
- ENSC N/A
- SILO N/A
- EPS
- ENSC N/A
- SILO N/A
- Revenue
- ENSC $6,224,081.00
- SILO $72,102.00
- Revenue This Year
- ENSC N/A
- SILO $1.86
- Revenue Next Year
- ENSC $1,381.48
- SILO N/A
- P/E Ratio
- ENSC N/A
- SILO N/A
- Revenue Growth
- ENSC 256.35
- SILO N/A
- 52 Week Low
- ENSC $1.62
- SILO $0.41
- 52 Week High
- ENSC $14.67
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- ENSC 49.40
- SILO 54.00
- Support Level
- ENSC $1.99
- SILO $0.56
- Resistance Level
- ENSC $2.25
- SILO $0.72
- Average True Range (ATR)
- ENSC 0.17
- SILO 0.07
- MACD
- ENSC -0.00
- SILO -0.00
- Stochastic Oscillator
- ENSC 47.62
- SILO 61.48
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.